Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

LOCKIT -SP1 and -SP2

99 years and younger
All genders
This is a 2 part study to better understand the differential pathogenesis between acute CLE, subacute CLE and chronic CLE, which may help in diagnosis and treatment choice. In SP1, participants will give samples during one visit including blood, skin biopsies, and other bodily fluids to analyze differential expression of …
Learn More

1305-0031

99 years and younger
All genders
This is an OLE for all subjects we currently have enrolled in BI 1305-0014 and 1305-0023. Subjects will be on either 9 mg or 18 mg of IP based on results from the current studies. Procedures involve safety labs, lung function testing, clinical labs, ECGs, PEs, AE collection.
Learn More

Hidradenitis Suppurativa Prospective Observational Registry

99 years and younger
All genders
The purpose of this study is to identify the clinical and biological characteristics of HS. Subject over the age of 18 diagnosed with HS will have one initial study visit and then be seen every 6 months during their standard routine clinic visit. First visit will consist of completing a …
Learn More

S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations

99 years and younger
All genders
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic).
Learn More

UPCC 27424 Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel

99 years and younger
All genders
The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.
Learn More

UPCC 32823 A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostat

99 years and younger
All genders
The intention of the study is to demonstrate superiority of AZD5305 + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Learn More

ATLAS-UC

99 years and younger
All genders
To evaluate the efficacy, safety, and tolerability of multiple does strengths of MK-7240 IV infusion and subcutaneous injection compared to Placebo as assessed by the proportion of participants achieving clinical remission per Modified Mayo Score, endoscopic improvements, at designated time points. Participants aged 16 to 75 years (inclusive) with moderately …
Learn More

NRG GI006 pHASE III TRIAL OF PBT VS IMRT FOR ESOPHAGEAL CANCER

99 years and younger
All genders
To determine if overall survival (OS) is improved with proton beam therapy (PBT) treatment as compared to intensity modulated radiation therapy (IMRT) as part of planned protocol treatment for patients with esophageal cancer. To determine if OS with PBT is non-inferior to IMRT as part of planned protocol treatment and …
Learn More

UPCC 22424: A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants with High-Risk Multiple Myeloma

99 years and younger
All genders
The purpose of this study is to see if using talquetamab either before or after ciltacabtagene autoleucel is safe and useful for treating patients with multiple myeloma. We would like to rely on Sterling IRB as the IRB of record for this study.
Learn More

UPCC 21424: A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

99 years and younger
All genders
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations. We would like to rely on Advarra as the …
Learn More
771 - 780 of 930